Enzo Biochem (NYSE:ENZ) Announces Quarterly Earnings Results

Enzo Biochem (NYSE:ENZGet Free Report) released its quarterly earnings results on Monday. The medical research company reported ($0.02) earnings per share for the quarter, Zacks reports. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.

Enzo Biochem Stock Performance

Shares of NYSE:ENZ opened at $0.47 on Tuesday. The company’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $0.87. Enzo Biochem has a 12-month low of $0.41 and a 12-month high of $1.30.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Enzo Biochem in a research report on Saturday. They set a “hold” rating on the stock.

Get Our Latest Report on ENZ

Enzo Biochem Company Profile

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

Featured Articles

Earnings History for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.